À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå : »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, À¯·¡ ¼¼Æ÷ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Induced Pluripotent Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Derived Cell Type, By Application, By End user By Region & Competition, 2020-2030F
»óǰÄÚµå : 1703309
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀåÀº 2024³â 14¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 9.60%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 14¾ï 5,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 25¾ï 2,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 9.60%
±Þ¼ºÀå ºÎ¹® ÀǾàǰ °³¹ß
ÃÖ´ë ½ÃÀå ºÏ¹Ì

iPS ¼¼Æ÷ ½ÃÀåÀº Àç»ýÀÇ·á ¹× ¼¼Æ÷Ä¡·á ºÐ¾ß¿¡¼­ ¿ªµ¿ÀûÀÌ°í ¹Ì·¡ÁöÇâÀûÀÎ ºÐ¾ß·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, iPS ¼¼Æ÷´Â ´Ù´É¼º »óÅ·ΠÃʱâÈ­µÈ ¼ºÃ¼ ¼¼Æ÷·Î °ÅÀÇ ¸ðµç À¯ÇüÀÇ ¼¼Æ÷·Î ºÐÈ­ÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °íÀ¯ÇÑ ´É·ÂÀ¸·Î ÀÎÇØ iPSC´Â Ä¡·áÁ¦ °³¹ß ¹× »ýÀÇÇÐ ¿¬±¸ ¸ðµÎ¿¡¼­ Áß¿äÇÑ ÀÚ»êÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¸¸¼ºÁúȯ Áõ°¡

ÀÌ·¯ÇÑ Àü·«Àû ¹æÇâ ÀüȯÀº ±âÁ¸ Ä¡·á¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â Áö¼Ó °¡´ÉÇÏ°í ¸ÂÃã Ä¡·á¹ýÀ¸·Î¼­ iPSC ±â¹Ý Ä¡·á¹ý¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁ³À½À» º¸¿©ÁÝ´Ï´Ù.

ÁÖ¿ä ½ÃÀå À̽´

¾ÈÀü°ú È¿°ú¿¡ ´ëÇÑ ¿ì·Á

ÁÖ¿ä ½ÃÀå µ¿Çâ

°³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ ¸ÂÃãÇü Ä¡·áÀÇ ¼ºÀå

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå PESTEL ºÐ¼®

Á¦14Àå PorterÀÇ Five Forces ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

Á¦16Àå Àü·«Àû Á¦¾È

Á¦17Àå ¸®¼­Ä¡»ç¿¡ ´ëÇØ & ¸éÃ¥»çÇ×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Induced pluripotent stem cells (iPSCs) market was valued at USD 1.45 billion in 2024 and is projected to exhibit strong growth throughout the forecast period, expanding at a compound annual growth rate (CAGR) of 9.60% through 2030.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.45 Billion
Market Size 2030USD 2.52 Billion
CAGR 2025-20309.60%
Fastest Growing SegmentDrug Development
Largest MarketNorth America

The iPSCs market has emerged as a dynamic and high-potential segment within the broader regenerative medicine and cell therapy landscape. iPSCs are adult cells reprogrammed to a pluripotent state, enabling them to differentiate into virtually any cell type. This unique capability makes iPSCs a critical asset in both therapeutic development and biomedical research.

Key Market Drivers

Rising Incidence of Chronic Diseases

The global surge in chronic, non-communicable diseases-including cardiovascular diseases, diabetes, neurodegenerative disorders such as Alzheimer's and Parkinson's, and various cancers-is placing significant strain on healthcare systems. These conditions collectively account for approximately 75% of global mortality and represent substantial clinical and economic burdens across both developed and developing regions.

This trend is directly contributing to the accelerated adoption of iPSCs, which offer transformative potential in disease modeling, drug discovery, and regenerative treatment development. Chronic diseases are typically progressive and require long-term, often lifelong, management. Traditional therapies frequently fall short in addressing the root causes or providing curative solutions.

iPSCs, by contrast, enable the regeneration of damaged or diseased tissues using cells derived from the patient, offering a novel therapeutic pathway. Industry research indicates that a significant portion of biopharmaceutical and medtech executives are prioritizing disruptive innovations-such as cell and gene therapies, including CAR-T and CRISPR-over incremental improvements to existing drugs and devices. Notably, 32% of biopharma leaders are focusing on such innovations, while 30% of medtech stakeholders are shifting investment toward breakthrough platforms, with 24% favoring the development of high-risk, high-reward Class III medical devices.

This strategic redirection underlines the growing confidence in iPSC-based therapies as sustainable, personalized alternatives to conventional treatments.

Key Market Challenges

Safety and Efficacy Concerns

Despite the significant promise of iPSCs, safety and efficacy concerns represent major barriers to their widespread clinical adoption. One of the most critical safety risks involves tumorigenesis; iPSCs, when transplanted, have the potential to form teratomas-tumors comprising various cell types-posing serious safety implications for patients.

Additionally, although iPSCs are often derived from a patient's own cells, issues with immune compatibility can still arise. Particularly in allogeneic applications, where donor-derived iPSC therapies are used, the risk of immune rejection remains a concern and must be carefully managed.

Efficacy also presents a key challenge. Demonstrating consistent and meaningful therapeutic outcomes in both preclinical and clinical settings is essential to gain regulatory approval and clinical trust. Long-term efficacy data, especially for chronic and degenerative conditions, are still being established.

Furthermore, the lack of standardized protocols for iPSC generation, differentiation, and quality control contributes to variability in cell quality and function. This inconsistency can impede reproducibility, scalability, and broader commercialization efforts.

Key Market Trends

Growth of Personalized Medicine and Patient-Specific Therapies

The growing shift toward personalized medicine is among the most significant trends shaping the iPSCs market. The ability to develop therapies tailored to individual genetic and immunological profiles is revolutionizing treatment paradigms, especially for chronic and complex diseases.

iPSCs facilitate the creation of patient-specific therapies by reprogramming somatic cells into a pluripotent state. These cells can then be genetically corrected-if necessary-and differentiated into therapeutic cell types. This personalized approach significantly reduces the risk of immune rejection and enhances therapeutic efficacy, offering hope for conditions that were previously considered untreatable.

In addition, iPSCs are enabling the creation of highly accurate disease models that reflect the patient's unique pathology. These models are invaluable for studying disease mechanisms, evaluating drug responses, and designing customized treatment strategies.

By minimizing the likelihood of adverse reactions and improving clinical outcomes, patient-specific iPSC-based therapies are reshaping expectations in regenerative medicine and significantly advancing the frontier of precision healthcare.

Key Market Players

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Market, By Derived Cell Type:

Induced Pluripotent Stem Cells Market, By Application:

Induced Pluripotent Stem Cells Market, By End User:

Induced Pluripotent Stem Cells Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.

Available Customizations:

Global Induced Pluripotent Stem Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Market Outlook

6. North America Induced Pluripotent Stem Cells Market Outlook

7. Europe Induced Pluripotent Stem Cells Market Outlook

8. Asia-Pacific Induced Pluripotent Stem Cells Market Outlook

9. South America Induced Pluripotent Stem Cells Market Outlook

10. Middle East and Africa Induced Pluripotent Stem Cells Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

16. Strategic Recommendations

17. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â